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Curcumin Selectively Induces Apoptosis in Cutaneous
T-Cell Lymphoma Cell Lines and Patients’ PBMCs:
Potential Role for STAT-3 and NF-jB Signaling
Chunlei Zhang1, Baoqiang Li1, Xiang Zhang1, Parul Hazarika1, Bharat B. Aggarwal2 and Madeleine Duvic1
Curcumin inhibits cell growth and induces apoptosis in a number of tumor cell lines and animal models.
Human clinical trials indicated no dose-limiting toxicity when administered at doses up to 8 g per day. The
purpose of this study was to address the antitumor effect of curcumin on cutaneous T-cell lymphoma (CTCL)
cell lines and peripheral blood mononuclear cells (PBMCs) from patients with CTCL compared with healthy
donors’ controls. Curcumin at 5–20 mM for 24 and 48hours induced apoptosis in a time- and dose-dependent
manner in three CTCL cell lines (namely MJ, Hut78, and HH). Curcumin at 5–20 mM for 48 hours also caused more
apoptosis in patients’ PBMCs compared with healthy donors’ PBMCs (Po0.05). Curcumin decreased protein
and mRNA expression levels of signal transducer and activator of transcription (STAT)-3, bcl-2, and survivin in
three cell lines and in patients’ PBMCs. Curcumin inhibited STAT-3 and IkB-a phosphorylation, as well as
suppressed DNA binding of nuclear factor (NF)-kB in these cells. Caspase-3 was activated and poly (ADP-Ribose)
polymerase was cleaved after curcumin treatment. These data suggest that curcumin selectively induces
apoptosis in association with the downregulation of STAT-3 and NF-kB signaling pathways in CTCL cells. Our
findings provide a mechanistic rationale for the potential use of curcumin as a therapeutic agent for patients
with CTCL.
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INTRODUCTION
Cutaneous T-cell lymphomas (CTCLs) are extranodal non-
Hodgkin’s lymphomas with pleomorphic skin lesions and
distinct T-cell markers. The incidence of CTCL at 6.4 per
million has doubled since the last analysis and it remains
more common in males and in African Americans (Criscione
and Weinstock, 2007). Mycosis fungoides (MF), the most
common and indolent form of CTCL, is characterized by
epidermotropic CD4þCD45ROþCLAþCCRþ helper/
memory T cells, which may lack CD7 and/or CD26
expression. Se´zary syndrome (SS), a leukemic variant, is
characterized with erythroderma and atypical cells in the
peripheral blood and by a peripheral blood T-cell clone
(Duvic and Foss, 2007). These malignant T cells exhibit
abnormal apoptotic mechanisms, such as loss of Fas or
expression of bcl-2, which result in the loss of activation-
induced cell death, prolonged life span, and accumulation
(Kacinski and Flick, 2001). There are a limited number of
Food and Drug Administration-approved therapeutic mod-
alities available to treat patients with MF/SS, including
bexarotene, intravenous denileukin diftitox, photopheresis,
and vorinostat (Duvic et al., 2001, 2007; Duvic and Foss,
2007). However, a number of nonapproved agents are
commonly used as a standard of care and include topical
steroids and mustargen, phototherapy, interferons, and
chemotherapy. Patients with refractory or transformed MF/
SS have a poor prognosis and therapy is usually palliative
(Kim et al., 2003). Alternative or complementary therapies,
especially for advanced MF/SS, are required.
Curcumin (diferuloylmethane) is the active compound in
turmeric (Curcuma longa), a dietary spice that has been
widely consumed for many centuries (Ammon and Wahl,
1991). This compound has been shown to interact with a
wide variety of proteins modifying their expression and
activity (Kunnumakkara et al., 2008). These include inflam-
matory cytokines and enzymes, transcription factors, and
gene products linked to cell survival, proliferation, invasion,
and angiogenesis. Curcumin has been found to exert
antiproliferative and proapoptotic effects in a number of
tumor cell lines in vitro (Moragoda et al., 2001; Bharti et al.,
2003; Li et al., 2004; Odot et al., 2004; Uddin et al., 2005). In
murine carcinoma models, curcumin has also been shown to
have chemopreventive effects, to reduce the number and size
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of tumors, and in some cases, to even ameliorate tumor-
induced immunodepletion of the host (Huang et al., 1988,
1994; Tanaka et al., 1994; Pal et al., 2001).
Phase I studies of curcumin have shown that this agent can
be administered safely at oral doses of up to 8 g per day with
no dose-limiting toxicity (Cheng et al., 2001; Sharma et al.,
2001, 2004). More recently, a phase II study of curcumin has
shown that this compound has biological activity in some
patients with pancreatic cancer, although its usefulness may
be attenuated because of its poor oral bioavailability (Dhillon
et al., 2008). Various approaches are being pursued to
overcome these limitations, which include synthesis of
curcumin analogs, the use of adjuvants (such as piperine),
and the development of improved delivery platforms for the
parental compound, such as liposomal, nanoparticulated, and
phospholipid complex formulations of curcumin (Anand et al.,
2007). Furthermore, this compound has been shown to have
therapeutic effects in other skin diseases, such as psoriasis,
scleroderma, and malignant melanoma (Heng et al., 2000;
Odot et al., 2004; Tourkina et al., 2004). In this study, we
examined the antitumor effects of curcumin on CTCL cell lines
and peripheral blood mononuclear cells (PBMCs) from MF/SS
patients with a high percentage of circulating tumor T cells
compared with healthy donors’ controls.
RESULTS
Curcumin treatment inhibited cell growth in CTCL cell lines
To determine whether curcumin can inhibit CTCL cell
growth, MJ, Hut78, and HH cells were treated with or
without 5, 10, and 20 mM curcumin for 24 and 48 hours, and
their viability was evaluated by CellTiter 96 AQueous One
Solution Cell Proliferation Assay. As the concentrations of
curcumin increased from 5 to 20 mM over 24 and 48 hours, the
cell growth of HH cells was inhibited by 11.7–84.9% and
32.8–94.9% in a dose- and a time-dependent manner,
respectively, compared with vehicle control (n¼3;
Po0.05). Similar results were also seen in MJ and Hut78
cell lines (Figure 1). These results show that curcumin is an
inhibitor of CTCL cell line growth in vitro.
Curcumin treatment induced apoptosis in CTCL cell lines
To determine whether the growth inhibition of CTCL cells by
curcumin results from apoptosis, MJ, Hut78, and HH cell
lines were treated with or without 5, 10, and 20 mM curcumin
for 24 and 48 hours. As curcumin concentrations increased
from 5 to 20 mM for 24 and 48 hours, the number of HH cells
staining for annexin V increased by 2.7–36.3% and
4.7–71.7% in a dose- and time-dependent manner, respec-
tively, compared with vehicle control (n¼ 3; Po0.05).
Similar results were also seen in MJ and Hut78 cell lines;
however, sensitivity to curcumin is different among the three
CTCL cell lines (Figure 2).
Curcumin treatment selectively induced apoptosis of MF/SS
patients’ PBMCs
To confirm the results from cell lines, we also tested the
proapoptotic effect of curcumin on freshly isolated PBMCs
from eight MF/SS patients with a high percentage
(43.8–98.2%) of circulating CD4þCD26 tumor T cells
and from three normal donors. As curcumin concentrations
increased from 5 to 20 mM for 48 hours, the number of
patients’ PBMCs stained for annexin V increased by
9.1–59.2% compared with vehicle control. As curcumin
concentrations increased from 5 to 20 mM for 48 hours, the
number of healthy donors’ PBMCs stained for annexin V
increased by 2.4–24.6% compared with vehicle control.
Thus, curcumin induced more apoptosis in MF/SS patients’
PBMCs than healthy donors’ PBMCs (Po0.05) (Table 1).
Curcumin treatment decreased expression of STAT-3 and
STAT-3-regulated antiapoptotic proteins in CTCL cell lines
and in patients’ PBMCs
Constitutive activation of signal transducer and activator of
transcription (STAT)-3 signaling has been shown to contribute
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Figure 1. Effect of curcumin on cell viability in CTCL cell lines. Cells (5104)
were aliquoted into a 96-well culture plate and grown in medium with or without
5, 10, or 20mM curcumin for 24 or 48hours. Cell viability was determined by
comparing untreated controls with treated groups using the CellTiter 96 AQueous
One Solution Cell Proliferation Assay performed in triplicate. Each point
represents mean±SD of triplicate determinations. *Significantly different from
control values (n¼ 3; Po0.05). CTCL, cutaneous T-cell lymphoma.
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to oncogenesis by stimulating cell proliferation and prevent-
ing apoptosis in CTCL (Eriksen et al., 2001; Nielsen et al.,
2002; Sommer et al., 2004). To determine whether STAT
signaling is involved in curcumin-induced apoptosis, we
examined the expression of STAT-3 and p-STAT-3 and their
regulated antiapoptotic proteins (bcl-2 and survivin) in three
CTCL cell lines (namely MJ, Hut78, and HH) and in four MF/
SS patients’ PBMCs after curcumin treatment at 10 mM for
24 hours. Western blotting results showed that expression
levels of both STAT-3 and p-STAT-3 proteins decreased by a
range of 21–55% and 38–47%, respectively, in these CTCL
cells compared with untreated controls (Figure 3a). More-
over, quantitative real-time PCR results showed that mRNA
expression levels of STAT-3 also decreased by 23–57%
compared with untreated controls (Figure 3b). Similar to
STAT-3, protein and mRNA expression levels of bcl-2
decreased by 22–94% and by 54–92%, respectively; and
protein and mRNA expression levels of survivin decreased by
11–95% and 50–83%, respectively compared with untreated
controls (Figure 4).
Curcumin treatment inhibited DNA binding of NF-jB and IjB-a
phosphorylation in CTCL cell lines and in patients’ PBMCs
The transcriptional factor nuclear factor (NF)-kB is constitu-
tively activated in CTCL and has been implicated in the
pathogenesis of this disorder (Sors et al., 2006; Do¨bbeling,
2007). To figure out whether NF-kB activation is involved in
curcumin-induced apoptosis, we examined DNA binding of
NF-kB in three CTCL cell lines (MJ, Hut78, and HH) and in
two patients’ PBMCs by electrophoretic mobility-shift assay.
Our results show that curcumin treatment at 10 mM for
24 hours inhibited the DNA binding of NF-kB in CTCL cell
lines and in patients’ PBMCs (Figure 5a). Moreover, to
investigate whether the inhibitory effect of curcumin is
mediated through the alteration of phosphorylation of IkB-
a, these CTCL cells were treated with curcumin, and their
protein extracts were checked for p-IkB-a expression. The
results showed that untreated CTCL cells constitutively
expressed p-IkB-a. Upon curcumin treatment, the ratio of
p-IkB-a and IkB-a decreased by 25–56% compared with
untreated controls (Figure 5b).
Curcumin treatment activated caspase-3 and cleaved PARP in
CTCL cell lines and in patients’ PBMCs
Caspase-3 is a key downstream target for both the intrinsic
and extrinsic apoptosis pathways (Porter and Ja¨nicke, 1999).
To determine whether caspase-3 activation is involved in
curcumin-induced apoptosis, we examined the expression of
caspase-3 and poly (ADP-Ribose) polymerase (PARP) proteins
in three CTCL cell lines (MJ, Hut78, and HH) and in four
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Figure 2. Effect of curcumin on apoptosis induction in CTCL cell lines. Three cell lines were treated with or without 5, 10, or 20 mM curcumin for 24 or 48 hours.
Annexin V binding was carried out using the Annexin V-FITC Detection Kit. (a) Curcumin induced a concentration- and time-dependent apoptosis in the HH cell
line. (b) Each point represents the percentage (mean±SD of triplicate determinations) of both annexin VþPI and annexin VþPIþ cells. *Significantly different
from control values (n¼3; Po0.05). CTCL, cutaneous T-cell lymphoma; FITC, fluorescein isothiocyanate; PI, propidium iodide.
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patients’ PBMCs. Western blotting results showed that
curcumin treatment activated capase-3 and cleaved PARP
as determined by the appearance of cleaved 17- and 20-kDa,
as well as 82-kDa fragments in CTCL cell lines and in
patients’ PBMCs, respectively (Figure 4a).
The autophagy inhibitor protected curcumin-induced cell
growth inhibition in CTCL cell lines
Although apoptosis induced by curcumin was associated
with caspase-3 activation in CTCL cells, we cannot exclude
other types of caspase-3-independent cell death. Thus, we
hypothesized that curcumin may also induce autophagy.
Three CTCL cell lines (MJ, Hut78, and HH) were pretreated
with 10 mM chloroquine (CQ), an inhibitor of autophagy
(Zhang et al., 2008), for 24 hours and then incubated with
curcumin at 10 mM for 48 hours. Our results showed that three
CTCL cell lines pretreated with CQ improved cell viability
relative to cells treated with curcumin alone by 12–19%
(Figure 6).
DISCUSSION
As defective apoptosis of skin-homing memory T cells is
involved in the pathogenesis of CTCL, pharmacological
modulation of apoptosis may provide new therapeutic
approaches (Kacinski and Flick, 2001; Meech et al., 2001).
The most effective treatments for MF/SS, including photo-
therapy (Baron and Stevens, 2003), photopheresis (Zic,
2003), the RXR (retinoid x receptor) selective retinoid
bexarotene (Zhang et al., 2002), and the histone deacetylase
inhibitor vorinostat (Zhang et al., 2005), induce apoptosis of
tumor T cells. In this study, we report that curcumin at
5–20 mM caused apoptosis in CTCL cell lines. More im-
portantly, our results showed that curcumin treatment
preferentially induced more apoptosis in PBMCs from
patients with a high percentage of circulating tumor T cells
compared with healthy donor controls. Previous studies have
shown that curcumin can selectively kill transformed tumor
cells from colon, breast, and liver cancers compared with
normal cells in vitro (Jiang et al., 1996; Ramachandran and
You, 1999; Choudhuri et al., 2005; Watson et al., 2008).
Moreover, curcumin selectively induced apoptosis in chronic
lymphocytic leukemia patients’ primary cells compared with
healthy donors’ mononuclear cells (Everett et al., 2007). The
selectivity of curcumin for cancer cells might be explained by
its ability to increase the cellular levels of reactive oxygen
species (Lopez-Lazaro, 2008). In addition, there is also
different sensitivity to curcumin in the three cell lines and
patients’ PBMCs. Further exploration is required to under-
stand the molecular basis of sensitivity difference to curcumin
in inducing apoptosis of different CTCL cell lines and
patients’ cells.
A possible mechanism underlying the induction of
apoptosis by curcumin could be its capacity to inhibit NF-kB
and STAT-3 signaling. NF-kB is well known as a transcription
factor that regulates the expression of a large number of genes
in response to various cellular conditions, including infec-
tion, inflammation, adhesion, cell cycle, and survival.
Activation of NF-kB can be controlled through the alteration
Table 1. Curcumin selectively induced apoptosis of MF/SS patients’ PBMCs
Apoptosis %1 (48 h)
Concentrations (lM)
Patient no. Age/gender Diagnosis CD4+CD26 (%) 5 10 20
1 55/F MF/SS 46.3 15.8% 54.9% 80.2%
2 61/F MF 43.8 0.5% 22.9% 68.8%
3 70/M SS 95.8 8.9% 14.4% 71.4%
4 53/F MF/SS 98.2 2.8% 8.0% 49.8%
5 58/M MF/SS 96.4 15.0% 23.5% 42.7%
6 51/M SS 77.1 13.7% 29.4% 46.2%
7 67/F SS 87.0 3.2% 19.4% 44.0%
8 71/M SS 93.0 13.2% 40.3% 70.7%
Statistic analysis
Total (mean+SD) Patients (n=8) 9.1±6.2 26.6±15.0 59.2±15.0
Healthy donors (n=3) 2.4±6.3 11.6±5.8 24.6±5.5
P-value Patients versus healthy donors P=0.20 P=0.04 P=0.0004
Abbreviations: MF, mycosis fungoides; PBMC, peripheral blood mononuclear cell; PI, propidium iodide; SS, Se´zary syndrome.
1Apoptosis was determined by flow cytometry analysis of annexin V/PI staining. The values represented the percentage of annexin V+PI and annexin V+PI+
binding from PBMCs treated with different concentrations of curcumin over vehicle control.
www.jidonline.org 2113
C Zhang et al.
Curcumin Selectively Induces Apoptosis in CTCL Cells
of phosphorylation of the IkB inhibitory protein, such as IkB-
a by IkB-a kinase (Aggarwal, 2004). In CTCL, constitutive
nuclear NF-kB activity is required for cell survival and
resistance to apoptosis in CTCL cells (Sors et al., 2006;
Do¨bbeling, 2007). This is manifested by the phosphorylation
of STAT-3, which results in impaired tumor cell apoptosis
(Eriksen et al., 2001; Nielsen et al., 2002; Sommer et al.,
2004). Constitutive activation of STAT-3 has also been shown
to contribute to oncogenesis by stimulating cell proliferation
and preventing apoptosis in a large number of solid tumors
and hematological malignancies, including CTCL (Sommer
et al., 2004; Turkson, 2004; Mitchell and John, 2005). Agents
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Figure 3. Effect of curcumin on the expression of STAT-3/p-STAT-3 proteins and STAT-3 mRNA in CTCL cell lines and in patients’ PBMCs. CTCL cells were
treated with or without 10mM curcumin for 24 hours. (a) Expression of STAT-3 and p-STAT-3 proteins was evaluated by western blots. The protein levels were
quantified and expression levels of STAT-3 protein from untreated control cells were used as 100%. (b) Expression of STAT-3 mRNA was examined by
quantitative real-time PCR assays. The expression levels of normalized STAT-3 mRNA from untreated control cells were used as 100%. The results were
expressed as mean±SD in three independent experiments. *Significantly different from control values (n¼ 3; Po0.05). CTCL, cutaneous T-cell lymphoma;
PBMC, peripheral blood mononuclear cell; STAT, signal transducer and activator of transcription.
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that suppress NF-kB and STAT-3 activity could be good
candidates for the treatment of CTCL, as they should be able
to induce apoptosis in CTCL cells. In this study, curcumin
treatment at concentrations causing apoptosis decreased the
protein and mRNA expression of STAT-3, as well as inhibited
activation of STAT-3 in CTCL cells. Curcumin treatment also
inhibited DNA binding of NF-kB through the suppression of
IkB-a phosphorylation in CTCL cells. Thus, downregulation
of STAT-3 signaling and inhibition of NF-kB activity may be
involved in curcumin-induced apoptosis of CTCL cells.
CTCL tumors remain restricted to the skin for most of the
time as the disease progresses. The low number of mitotic
cells led to the idea that the increase in tumor mass is due to
the overexpression of cell survival genes such as bcl-2, which
R
el
at
ive
 le
ve
ls
 o
f
bc
l-2
 p
ro
te
in
 (%
 co
ntr
ol)
MJ
Control
Curcumin
Hut78 HH PT1 PT2 PT3 PT4
100100100100100100100
5 14 60 40 89 719
MJ
Control
Curcumin
Hut78 HH PT1 PT2 PT3 PT4
100100100100100100100
16 6 65 44 51 4578
120
100
80
60
40
20
0
R
el
at
ive
 le
ve
ls
 o
f s
ur
vi
vi
n
pr
ot
ei
n 
(%
 co
ntr
ol)
120
100
80
60
40
20
0
MJ
Control
Curcumin
Hut78 HH
*
*
* *
*
*
*
*
**
PT1 PT2
100100100100100
34 46 9 40 8
MJ
Control
Curcumin
Hut78 HH PT1 PT2
100100100100100
17 43 38 50 33
N
or
m
a
liz
e
d
bc
l-2
 m
RN
A 
(%
 co
ntr
ol)
N
or
m
a
liz
e
d 
su
rv
iv
in
m
R
N
A 
(%
 co
ntr
ol)120
140
100
80
60
40
20
0
120
140
100
80
60
40
20
0
Curcumin
MJ Hut78 HH PT1 PT2 PT3
29 kDa
– + – + – + – + – + – + – +
14.5 kDa
20 kDa
17 kDa
116 kDa
82 kDa
46 kDa
PT4
Bcl-2
Survivin
Cleaved caspase-3
PARP
Actin
a
b
Figure 4. Effect of curcumin on the expression of apoptosis-related proteins and mRNAs in CTCL cell lines and in patients’ PBMCs. CTCL cells were
treated with or without 10 mM curcumin for 24 hours. (a) Expression of apoptosis-related proteins was evaluated by western blots. The protein levels were
quantified and expression levels of bcl-2 and survivin proteins from untreated control cells were used as 100%. (b) Expression of bcl-2 and survivin mRNAs
was examined by quantitative real-time PCR assay. The expression levels of normalized bcl-2 and survivin mRNAs from untreated control cells were used as
100%. The results were expressed as mean±SD in three independent experiments. *Significantly different from control values (n¼3; Po0.05). CTCL,
cutaneous T-cell lymphoma; PBMC, peripheral blood mononuclear cell.
www.jidonline.org 2115
C Zhang et al.
Curcumin Selectively Induces Apoptosis in CTCL Cells
protect tumor cells from apoptosis rather than oncogenes that
promote cell growth (Korsmeyer, 1992). Indeed, the anti-
apoptotic genes bcl-2, bcl-xL, and mcl-1 are expressed in
CTCL cells, and their expression levels increase with
progression of the disease (Zhang et al., 2003). Bcl-2 is a
downstream target of STAT-3 signaling and is critical in
controlling the activation of caspases by regulating the
release of cytochrome c from the mitochondria (Manion
and Hockenbery, 2003). Bcl-2 expressed in CTCL cells
may increase survival and resistance of CTCL cells against
radiotherapy and extracorporeal photochemotherapy
(Osella-Aate et al., 2001; Breuckmann et al., 2002; Zhang
et al., 2003). In addition, survivin is a downstream target of
NF-kB signaling and is a member of the inhibitor of apoptosis
protein family (Ambrosini et al., 1997). Survivin suppresses
caspase activity and protects cells from apoptosis (LaCasse
et al., 1998). We have previously shown that CTCL cells
express the survivin protein, and its expression decreases after
bexarotene or avicin D treatment (Zhang et al., 2002, 2008).
In this study, curcumin treatment decreased protein and
mRNA levels of both bcl-2 and survivin in CTCL cell lines
and in MF/SS patients’ PBMCs. This suggests that the
downregulation of bcl-2 and survivin may be involved in
curcumin-induced apoptosis in CTCL cells.
Curcumin has been shown to induce apoptosis through
caspase-3-dependent or caspase-3-independent manner in a
number of transformed tumor cells (Lopez-Lazaro, 2008).
Caspase-3 is a key component of apoptosis, is activated in
apoptotic cells, and cleaves cellular proteins, including PARP
(Porter and Ja¨nicke, 1999). Cleavage of PARP is a hallmark of
apoptosis induced by various antitumor agents (Duriez and
Shah, 1997). We have previously reported that caspase-3 is
activated and PARP is cleaved in apoptotic CTCL cells after
treatment with the RXR-selective retinoid bexarotene (Zhang
et al., 2002), and with the histone deacetylase inhibitor
vorinostat (Zhang et al., 2005). In this study, we show that
curcumin treatment at concentrations inducing apoptosis also
activated caspase-3 and cleaved PARP in CTCL cell lines and
patients’ PBMCs. Thus, curcumin-induced apoptosis is at
least partially dependent on caspase-3 in CTCL cells.
However, other types of cell death, in particular autophagy,
may also be involved in curcumin-induced cell death in
CTCL cells. Indeed, recent studies have shown that curcumin
also induces autophagy, another type of programmed cell
death (Lopez-Lazaro, 2008). It is interesting that our
preliminary data showed that CTCL cells pretreated with
the autophagy inhibitor CQ improved cell viability relative to
cells treated with curcumin alone, suggesting that curcumin
may also induce autophagy in CTCL. Further experiments for
detecting autophagy such as autophagosomes are required to
confirm our above observation in CTCL.
In conclusion, curcumin selectively induces apoptosis in
CTCL cell lines and MF/SS patients’ PBMCs compared with
healthy donors’ controls. These events are associated with
downregulation of STAT-3, inhibition of DNA binding of
NF-kB through suppression of phosphorylation of IkB-a,
decreased mRNA and protein expression of bcl-2 and
survivin, and activation of caspase-3 in CTCL cells. Our
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findings provide a mechanistic rationale for the potential use
of curcumin as a therapeutic agent for patients with CTCL.
MATERIALS AND METHODS
Reagents
Curcumin (495% pure) was purchased from LKT Laboratories
(St Paul, MN). Curcumin was dissolved in dimethyl sulfoxide to a
stock concentration of 20mM and stored at 80 1C. Serial dilutions
(5, 10, and 20mM) were freshly prepared in RPMI 1640. CQ was
purchased from Sigma-Aldrich (St Louis, MO) and was dissolved in
phosphate-buffered saline to a stock concentration of 20mM.
Cells and cell culture
The human CTCL cell lines MJ (G11), Hut78, and HH, obtained from
the American Type Culture Collection (Rockville, MD), were derived
from the peripheral blood of patients with MF, SS, and non-MF/SS
aggressive CTCL, respectively (Gootenberg et al., 1981; Popovic
et al., 1983; Starkebaum et al., 1991). Samples of peripheral blood
were obtained for in vitro studies from three healthy donors and
eight MF/SS patients with 43.8–98.2% circulating CD4þCD26
tumor T cells (Bernengo et al., 2001) (Table 1). Samples were
obtained during routine diagnostic assessments. The Institutional
Review Board of the University of Texas MD Anderson Cancer
Center approved this study and the participants gave written
informed consent. This study was conducted according to the
Declaration of Helsinki Principles. PBMCs from these healthy donors
and patients were isolated by Vacutainer CPT (Becton Dickinson,
San Jose, CA). Cells were grown in RPMI 1640 medium (Sigma-
Aldrich) supplemented with 10% heat-inactivated fetal bovine serum
(HyClone Laboratories, Logan, UT), 2mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), and 1% penicillin–strepto-
mycin in a humidified atmosphere with 5% CO2 at 37 1C.
Cell viability
Cell viability was measured by CellTiter 96 AQueous One Solution
Cell Proliferation Assay according to the manufacturer’s instructions
(Promega, Madison, WI). Aliquots of 5 104 cells per well were
distributed in 96-well microplates (Falcon, Franklin Lakes, NJ) in
100ml of medium and incubated with 5, 10, and 20 mM curcumin or
10 mM CQ for 24 and/or 48 hours, and then 20 ml of 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt was added to each well and incubated for
an additional 4 hours. The relative cell viability was determined at
490 nm using a 96-well plate reader. Each experiment was
performed in triplicate, and repeated a minimum of three times.
Annexin V binding staining
Analysis of annexin V binding was carried out using an Annexin V-
fluorescein isothiocyanate Detection Kit I (PharMingen, San Diego,
CA) according to the manufacturer’s instructions. Briefly, three cell
lines (MJ, Hut78, and HH) and PBMCs from three healthy donors
and eight MF/SS patients were incubated with or without curcumin
(5, 10, and 20 mM) for 24 and/or 48 hours. Cells were collected,
washed twice with cold phosphate-buffered saline, and centrifuged
at 1,500 r.p.m. for 5minutes. Cells were resuspended in 1 binding
buffer at a concentration of 1 106 cells per ml, 100ml of the
solution was transferred into a 5ml culture tube, and 5ml of annexin
V-fluorescein isothiocyanate and 5 ml of PI (propidium iodide) were
added. Cells were gently vortexed, and incubated for 15minutes at
room temperature in the dark. Finally, 400ml of 1 binding buffer
was added to each tube, and samples were analyzed using FACScan
flow cytometer (Becton Dickinson). For each sample, 10,000
ungated events were acquired. Annexin VþPI cells represented
the early apoptotic populations. Annexin VþPIþ cells represented
either late apoptotic or secondary necrotic populations.
Isolation of cytoplasmic and nuclear extracts
Cells (5 106) were washed with ice-cold phosphate-buffered
saline, harvested into 1ml of phosphate-buffered saline, pelleted in
a 1.5-ml microcentrifuge tube, and suspended in 400 ml of buffer A
(10mM HEPES (pH 7.9), 10mM KCl, 1mM EDTA, 1mM EGTA, 1mM
DTT, and 1 protease inhibitor cocktail ‘‘complete mini’’ (Roche,
Indianapolis, IN)). After a 20-minute incubation on ice, the mixture
was treated with a 24-G syringe for five times and then centrifuged
briefly to obtain the cytoplasmic supernatant. The nuclear pellet was
resuspended in 40–80 ml of buffer C (10mM HEPES (pH 7.9), 10mM
KCl, 1mM EDTA, 1mM EGTA, 1mM DTT, 10% glycerol, and 1
protease inhibitor cocktail ‘‘complete mini’’ (Roche)) and incubated
at 4 1C by shaking for 15minutes. Protein concentrations were
determined by the Bradford dye-binding protein assay (Bio-Rad,
Richmond, CA) using bovine serum albumin as a standard.
Western blot analysis
Western blotting was performed as described previously (Zhang
et al., 2002). Briefly, cytoplasmic (10 mg) or nuclear (5mg) proteins
were subjected to SDS-PAGE (8–12%) electrophoresis and trans-
ferred onto nitrocellulose membranes (Schleicher & Schuell, Dasse,
Germany). The membranes were blocked in 3% powdered milk in
TBST (50mM Tris (pH 7.5), 150mM NaCl, 0.05% Tween 20) for
1 hour at room temperature, incubated with primary antibodies
overnight at 4 1C in 3% powdered milk in TBST, and washed
extensively with TBST. They were incubated with 1:5,000 perox-
idase-conjugated anti-mouse or anti-rabbit secondary antibody
(Jackson ImmunoResearch, West Grove, PA) for 1 hour at room
temperature. Monoclonal mouse anti-STAT-3 (1:1,000) antibody
was obtained from BD Bioscience (San Diego, CA). Monoclonal
mouse anti-bcl-2 (1:2,000), anti-survivin (1:500), anti-PARP
(1:1,000), and anti-actin (1:2,000) antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal mouse
anti-phospho-STAT-3 (p-STAT-3) (1:1,000), anti-IkB-a (1:1,000),
anti-phospho-IkB-a (p-IkB-a) (1:1,000), and rabbit anti-cleaved
caspase-3 (1:1,000) antibodies were obtained from Cell Signaling
(Beverly, MA). Immunoreactive bands were visualized using
enhanced chemiluminescence detection kit (Amersham, Buckin-
ghamshire, UK), and equivalent loading of proteins in each well was
confirmed by actin and Ponceau staining. The protein levels were
quantified using an AlphaEase 4.0 Imager (Alpha Innotech, San
Leandro, CA).
Electrophoretic mobility-shift assay
For NF-kB binding activity, a nonradioactive electrophoresis
mobility-shift assay kit was used according to the manufacturer’s
instructions (Panomics, Fremont, CA). Briefly, three CTCL cell lines
and PBMCs from two MF/SS patients were incubated with or without
curcumin (10 mM) for 24 hours. In all, 5mg of nuclear extracts was
incubated 15 1C for 30minutes with a biotinylated oligonucleotide
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containing the NF-kB binding site, and then the samples were
separated on 6.0% nondenaturing polyacrylamide gel in 0.5 TBE
buffer for 55minutes at 120V at 4 1C. The gel contents were
transferred into Biodyne B membrane (Pall, Ann Arbor, MI) for
45minutes at 300mA. The biotinylated nucleotides were detected
using detected reagent (Panomics).
Quantitative real-time PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. The first-
strand cDNA was synthesized from total RNA by reverse transcrip-
tion using the SuperScript III First-Strand Synthesis System (Invitro-
gen, Carlsbad, CA) according to the manufacturer’s instructions.
Gene-specific quantitative real-time PCR assays for STAT-3, bcl-2,
survivin, and GAPDH (glyceraldehyde 3-phosphate dehydrogenase)
(SABiosciences, Frederick, MD) were performed using a Biosystem
7000 sequencer (Applied Biosystems, Foster City, CA) according to
the manufacturer’s instructions. GAPDH was used as an internal
standard of mRNA expression for normalization. Samples were run
in triplicates with one control reaction containing no reverse-
transcriptase enzyme to test for potential DNA contamination. Wells
with no template were used as negative control.The results were
expressed as mean±SD in three independent experiments.
Statistical analysis
All experiments were performed in triplicate unless otherwise noted.
Results were expressed as means±SD. Statistical significance was
evaluated by Student’s t-test, and Po0.05 was considered as
significant.
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